Patent application number | Description | Published |
20100266626 | ADJUVANTED GLUCANS - The use of beta-glucans as antigens for immunising against fungi is known. According to the invention, the beta-glucans are administered together with an adjuvant. The adjuvant improves the immune response. The glucan will usually be conjugated to a carrier. Suitable glucans include laminarin and curdlan. | 10-21-2010 |
20100272755 | FERMENTATION PROCESSES FOR CULTIVATING STREPTOCOCCI AND PURIFICATION PROCESSES FOR OBTAINING CPS THEREFROM - This invention is in the field of bacterial cultures and specifically relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from | 10-28-2010 |
20110045015 | CONJUGATED BETA-1,3-LINKED GLUCANS - Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolysed to a suitable form prior to conjugation. | 02-24-2011 |
20110142876 | CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM | 06-16-2011 |
20110159602 | ANALYSIS OF VI SACCHARIDES - Vi saccharide can be assayed in two new ways. First, its proton NMR spectrum can be used, with comparison to an internal Standard permitting quantitative analysis. Second, anion exchange chromatography with amperometric detection can be used on hydrolysed saccharide. | 06-30-2011 |
20120282295 | PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR SACCHARIDES - The invention provides a method for releasing capsular polysaccharide from | 11-08-2012 |
20120308600 | POLYSACCHARIDE IMMUNOGENS CONJUGATED TO E. COLI CARRIER PROTEINS - proteins have been identified that are useful as carrier proteins to improve a response to a polysaccharide immunogen conjugated to such protein. In particular, AcfD precursor protein (orf3526 polypeptide), Flu antigen 43 protein (orf1364 polypeptide), and Sel1 repeat-containing protein (upec-5211 polypeptide) have been shown to be effective. Additionally, these | 12-06-2012 |
20130142822 | CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM | 06-06-2013 |
20130273091 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype 1a conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype 1b conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof. | 10-17-2013 |
20140011183 | FERMENTATION PROCESSES FOR CULTIVATING STREPTOCOCCI AND PURIFICATION PROCESSES FOR OBTAINING CPS THEREFROM - This invention is in the field of bacterial cultures and specifically relates to the optimization of culture conditions to improve the production of bacterial capsular polysaccharides from | 01-09-2014 |
20140335544 | METHOD OF DETECTING THE PRESENCE OF AN ANTIBODY IN A SAMPLE - Methods for detecting in a sample the presence of an antibody to a conjugate of an antigen associated with a first carrier by a first association are disclosed. The method comprises contacting a conjugate of the antigen associated with a second carrier by a second association with said sample under conditions that allow binding of the antibody to the antigen; and introducing an agent to detect the presence of the antibody bound to said antigen. The first association and the second association are covalent associations and the first association is different from the second association. Also provided are kits, multiwell plates and conjugates that are useful in the method and further uses of the method. Also provided is a method of releasing a batch of a vaccine comprising a conjugate of an antigen associated with a first carrier by a first association and antibodies useful in this method. | 11-13-2014 |
20150283232 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising: (a) a conjugate that is a capsular saccharide from GBS serotype I1 conjugated to a carrier protein; (b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; and (c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunizing a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunized with a diphtheria toxoid or derivative thereof. | 10-08-2015 |
20150315225 | PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR SACCHARIDES - The invention provides a method for releasing capsular polysaccharide from | 11-05-2015 |
20160051667 | CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR POLYSACCHARIDES - The invention provides a process for preparing a conjugate of a | 02-25-2016 |
Patent application number | Description | Published |
20090043077 | Conjugation of streptococcal capsular saccharides - Three conjugation methods for use with the capsular saccharide of | 02-12-2009 |
20090136547 | ZWITTERIONIZATION OF CAPSULAR SACCHARIDES - Capsular saccharides are typically anionic. In the invention, however, cationic groups are introduced, such that the modified saccharide has a repeating unit which includes both cationic and anionic groups. These cationic and anionic groups can be balanced to give a zwitterionic repeating unit. These modifications can convert a saccharide that is normally a T-independent antigen into one that can activate T cells without requiring conjugation to a carrier. Typically, the invention modifies an anionic bacterial capsular saccharide antigen by converting a neutral group in the saccharide into a cationic group e.g. to change —NHAc to —NH | 05-28-2009 |
20090176311 | SEPARATION OF CONJUGATED AND UNCONJUGATED COMPONENTS - The invention is based on the use of a basic reagent under basic conditions to separate conjugated saccharide from unconjugated components in a sample, e.g. a vaccine, by precipitation of the conjugated saccharide. The invention allows rapid and quantitative separation of conjugated and conjugated components, which may be exploited in analytical methods for quantifying unconjugated saccharide or carrier. Therefore, the separation of conjugated and unconjugated components using the invention may be advantageously combined with a quantitative saccharide or carrier analysis to provide improved quality control for conjugate vaccines. | 07-09-2009 |
20100092509 | Hypo- and Hyper- Acetylated Meningococcal Capsular Saccharides - Capsular saccharides derived from serogroups W135 and Y of | 04-15-2010 |
20100239600 | CONJUGATE PURIFICATION - This application relates to methods for the purification of saccharide antigen-carrier protein conjugates. In particular, the invention provides a method for purifying saccharide antigen- carrier protein conjugates from free carrier protein, such as CRM1 97, using hydroxyapatite. The invention further relates to methods of preparing vaccines, using this method. | 09-23-2010 |
20100322958 | MODIFIED SACCHARIDES - Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R | 12-23-2010 |
20120010398 | PURIFICATION METHOD - A process for purifying a | 01-12-2012 |
20130295132 | Conjugation of Streptococcal Capsular Saccharides - Three conjugation methods for use with the capsular saccharide of | 11-07-2013 |
20130315959 | COMPOUNDS - The invention provides a synthetic | 11-28-2013 |
20130315960 | CONJUGATED BETA-1,3-LINKED GLUCANS - Glucans having exclusively or mainly β-1,3 linkages are used as immunogens. These comprise β-1,3-linked glucose residues. Optionally, they may include β-1,6-linked glucose residues, provided that the ratio of β-1,3-linked residues to β-1,6-linked residues is at least 8:1 and/or there are one or more sequences of at least five adjacent non-terminal residues linked to other residues only by β-1,3 linkages. The glucans will usually be used in conjugated form. A preferred glucan source is curdlan, which may be hydrolysed to a suitable form prior to conjugation. | 11-28-2013 |
20140141034 | TYROSINE LIGATION PROCESS - A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain | 05-22-2014 |
20140234368 | HYPO- AND HYPER-ACETYLATED MENINGOCOCCAL CAPSULAR SACCHARIDES - Capsular saccharides derived from serogroups W135 and Y of | 08-21-2014 |
20150104479 | MENINGOCOCCUS SEROGROUP X CONJUGATE - The invention provides a conjugate of a | 04-16-2015 |
20150231231 | Conjugation of Streptococcal Capsular Saccharides - Three conjugation methods for use with the capsular saccharide of | 08-20-2015 |